Full Name
Martin Gershon
Name of ACA member affiliation or organization
Endeavor Venture Funds & Venture Studios
Speaker Bio
Dr. Martin Gershon is Managing Partner and CIO of Endeavor Venture Funds and Venture Studio and it’s Strategy Consulting arm Endeavor Life Sciences Growth Advisors.
He is a prominent Venture Investor & entrepreneur, featured on CNBC, contributing author for Fast Company, Techstars Lead Mentor, MassChallenge Expert, HBS Healthcare Alumni Association member, Leading Life Sciences Innovation Strategist, Futurist and Go-to-Market Advisor for emerging Unicorns and Fortune 500 Companies and industry leaders such as McKinsey, American Express, Fidelity, Tiger Global, Pfizer, Novartis, Bain Capital, Federal Reserve Board of Governors, and The Bill and Melinda Gates Foundation.
Over the past 23 years Dr. Gershon raised over $1B, personally started and exited 6 startups, has expanded and developed an ecosystem of collaboration partners within Big Tech, Digital Healthcare, Pharma, Biotech, Medtech, world class accelerators Techstars and MassChallenge, and prominent Ivy League universities and business schools Harvard, Columbia, and NYU, leveraging core competencies of the partnerships and providing transformative innovation and technology solutions to emerging healthcare and life science companies.
As the Managing Partner of Endeavor Dr. Gershon is the architect driving a team of 22 professionals to leverage Endeavor’s ecosystem of collaboration partnerships to provide CEO/Entrepreneurs Founders with bespoke revenue generating Go-to-Market strategies, FDA regulatory services, clinical trial design and reimbursement and coding guidance, and the development of strategic and financial corporate partnerships to grow, scale, and commercialize disruptive new healthcare and life sciences products and services stemming from technologies like AI and ML.
Endeavor Venture Fund is an evergreen Swiss Healthcare and Life Sciences Fund, established in 2009. Endeavor Venture Fund I invested in groundbreaking companies like Moderna and 69 life science companies with 55 exits. Endeavor’s companies possess disruptive technologies with strong scalable commercial potential, driven by great entrepreneur/founders who look for coaching and partnerships within our ecosystem to enhance and build their companies into the next great unicorn.
He is a prominent Venture Investor & entrepreneur, featured on CNBC, contributing author for Fast Company, Techstars Lead Mentor, MassChallenge Expert, HBS Healthcare Alumni Association member, Leading Life Sciences Innovation Strategist, Futurist and Go-to-Market Advisor for emerging Unicorns and Fortune 500 Companies and industry leaders such as McKinsey, American Express, Fidelity, Tiger Global, Pfizer, Novartis, Bain Capital, Federal Reserve Board of Governors, and The Bill and Melinda Gates Foundation.
Over the past 23 years Dr. Gershon raised over $1B, personally started and exited 6 startups, has expanded and developed an ecosystem of collaboration partners within Big Tech, Digital Healthcare, Pharma, Biotech, Medtech, world class accelerators Techstars and MassChallenge, and prominent Ivy League universities and business schools Harvard, Columbia, and NYU, leveraging core competencies of the partnerships and providing transformative innovation and technology solutions to emerging healthcare and life science companies.
As the Managing Partner of Endeavor Dr. Gershon is the architect driving a team of 22 professionals to leverage Endeavor’s ecosystem of collaboration partnerships to provide CEO/Entrepreneurs Founders with bespoke revenue generating Go-to-Market strategies, FDA regulatory services, clinical trial design and reimbursement and coding guidance, and the development of strategic and financial corporate partnerships to grow, scale, and commercialize disruptive new healthcare and life sciences products and services stemming from technologies like AI and ML.
Endeavor Venture Fund is an evergreen Swiss Healthcare and Life Sciences Fund, established in 2009. Endeavor Venture Fund I invested in groundbreaking companies like Moderna and 69 life science companies with 55 exits. Endeavor’s companies possess disruptive technologies with strong scalable commercial potential, driven by great entrepreneur/founders who look for coaching and partnerships within our ecosystem to enhance and build their companies into the next great unicorn.
Speaking At
